Welcome to LookChem.com Sign In|Join Free
  • or
Benzenemethanol, 2,6-dimethyl-3-nitro-, methanesulfonate (ester) is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

179626-80-3

Post Buying Request

179626-80-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

179626-80-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 179626-80-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,9,6,2 and 6 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 179626-80:
(8*1)+(7*7)+(6*9)+(5*6)+(4*2)+(3*6)+(2*8)+(1*0)=183
183 % 10 = 3
So 179626-80-3 is a valid CAS Registry Number.

179626-80-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name 2,6-dimethyl-3-nitrobenzyl methanesulfonate

1.2 Other means of identification

Product number -
Other names Methanesulfonic acid 2,6-dimethyl-3-nitro-benzyl ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:179626-80-3 SDS

179626-80-3Relevant academic research and scientific papers

Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators

-

Page 26, (2010/02/08)

This invention is directed towards novel alkylamide derivatives as bradykinin receptor antagonists useful for the treatment of bradykinin modulated disorders such as pain, inflammation, asthma and allergy. Furthermore, the present invention is directed to novel alkylamide derivatives as bradykinin receptor agonists useful for the treatment of bradykinin modulated disorders such as hypertension and the like.

NOVEL HETEROARYL ALKYLAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR MODULATORS

-

Page/Page column 54-55, (2010/02/07)

This invention is directed towards novel alkylamide derivatives as bradykinin receptor antagonists useful for the treatment of bradykinin modulated disorders such as pain, inflammation, asthma and allergy. Furthermore, the present invention is directed to novel alkylamide derivatives as bradykinin receptor agonists useful for the treatment of bradykinin modulated disorders such as hypertension and the like.

Heterocyclic compounds as bradykinin antagonists

-

Page column 24, (2010/02/04)

This invention relates to a compound of the formula: wherein A1is lower alkylene, R1is substituted quinolyl, etc., R2is hydrogen, halogen or lower alkyl, R3is halogen or lower alkyl, and R4is a group

Pyridopyrimidones, quinolines and fused N-heterocycles as bradykinin antagonists

-

, (2008/06/13)

This invention relates to a compound of the formula: STR1 wherein Z is a group of the formula: STR2 in which X1 is N or C--R1, X2 is N or C--R9, X3 is N or C--R2, R1 is lower alk

Heterocyclic compounds as bradykinin antagonists

-

, (2008/06/13)

This invention relates to a compound of formula (I) wherein A1 is lower alkylene, R1 is substituted quinolyl, etc., R2 is hydrogen, halogen or lower alkyl, R3 is halogen or lower alkyl, and R4 is a gr

Novel series of O-substituted 8-quinolines and 4-benzothiazoles as potent antagonists of the bradykinin B2 receptors

Heitsch, Holger,Wagner, Adalbert,Schoelkens, Bernward A.,Wirth, Klaus

, p. 327 - 332 (2007/10/03)

The synthesis and the SAR study of novel O-substituted 8-quinolines and 4-benzothiazoles as highly potent non-peptide bradykinin B2 receptor antagonists are described. Several members of this series of antagonists efficiently inhibited the BK-induced vasoconstriction on different isolated organ preparations.

Studies on anti-Helicobacter pylori agents. Part 1: Benzyloxyisoquinoline derivatives

Yoshida, Yoshiki,Barrett, David,Azami, Hidenori,Morinaga, Chizu,Matsumoto, Satoru,Matsumoto, Yoshimi,Takasugi, Hisashi

, p. 2647 - 2666 (2011/05/18)

The synthesis and optimization of the anti-Helicobacter pylori activity of a novel series of benzyloxyisoquinoline derivatives that was discovered by a random screening process, are described. In the in vitro assay, compound 10c containing a 3-acetamido-2,6-dichlorobenzyl substituent was found to have extremely potent activity against H. pylori and no activity against other common bacteria. The anti-H. pylori activity of 10c was superior to that of amoxicillin (AMPC) (1) and clarithromycin (CAM) (2). However, 10c did not show in vivo efficacy in a mouse infection model; a feature attributed to the lack of strong bactericidal activity at short contact times. (C) 1999 Elsevier Science Ltd.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 179626-80-3